Belite Bio (BLTE) Interest & Investment Income (2024 - 2025)

Belite Bio (BLTE) posted quarterly Interest & Investment Income of $3.2 million for Q4 2025, up 155.6% year-over-year from $1.2 million in Q4 2024, and up 155.6% on a QoQ basis from $1.2 million in Q4 2024.

Belite Bio (BLTE) Interest & Investment Income (2024 - 2025) Analysis & Trends

Belite Bio (BLTE) has reported Interest & Investment Income for 2 consecutive years, with $3.2 million the latest figure, recorded in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int & Inv Inc (Qtr)
1 Genmab A 276,399.99 Bn 276,398.47 Bn 831.00 Mn 44.00 Mn
2 Akari Therapeutics 1,217.26 Bn 1,217.26 Bn - -
3 BeOne Medicines 419.38 Bn 414.59 Bn 1.35 Bn 27.66 Mn
4 Vertex Pharmaceuticals 126.54 Bn 119.30 Bn 2.59 Bn 114.80 Mn
5 Pharming 110.17 Bn 110.12 Bn 65.80 Mn -
6 Regeneron Pharmaceuticals 64.97 Bn 56.22 Bn 3.31 Bn -
7 Argenx Se 56.44 Bn 56.44 Bn 1.18 Bn 44.00 Mn
8 Alnylam Pharmaceuticals 40.09 Bn 37.08 Bn 959.66 Mn 26.60 Mn
9 Revolution Medicines 37.15 Bn 37.15 Bn - 19.51 Mn
10 Belite Bio 96.77 Mn 96.77 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 3.17 Mn
Dec 31, 2024 1.24 Mn